RiVive™ (naloxone HCl nasal spray 3 mg) is now available

RiVive – Harm Reduction Therapeutics’ new FDA approved over-the-counter emergency treatment for opioid overdose is now available for ordering and shipment. 

RiVive™ is an emergency treatment for opioid overdose

RiVive (naloxone HCI nasal spray 3mg) was recently approved by the FDA as an over-the-counter emergency treatment for opioid overdose. It is used to “revive” someone during an overdose from many prescription pain medications or street drugs. This medicine can save a life.

RiVive was developed by Harm Reduction Therapeutics, a 501(c)(3) nonprofit pharmaceutical company whose mission is to save lives that will otherwise be lost to opioid overdose. To make a charitable contribution to help us continue our mission, click here.

Naloxonoe Molecule C19 H21 NO4


Naloxone is the active ingredient in RiVive nasal spray. Naloxone quickly reverses an overdose by blocking the effects of opioids. It can restore normal breathing within 2 to 3 minutes in a person whose breath has slowed, or even stopped, as a result of opioid overdose. More than one dose of naloxone may be required when stronger opioids like fentanyl are involved.

Naloxone’s approval in 1971 led to increasingly widespread use as standard equipment in emergency medicine in the 1980s before being distributed by harm reduction in the 1990s as part of their public health initiatives. Intranasal naloxone is a well-established way to provide safe, rapid, and effective reversals of opioid overdoses.


With additional funding partners, Harm Reduction Therapeutics is focused on supplying RiVive™ to communities who need it most by donating 200,000 doses (10% of projected initial annual production). 


Our production process is now in full swing, and we recently completed our first shipment.

U.S. Harm Reduction organizations, state and other government procurement functions can order FDA-approved RiVive™ for the emergency treatment of opioid overdose by contacting (888) 412-7454 or by emailing sales@harmreductiontherepeutics.org.

RiVive™, which can save lives, will be available at cost or less, with its initial selling price set at $36 per twin pack. This price covers the hard costs (inactive ingredients, devices, vials) and production, packaging, testing, and transportation costs (92% of the price) plus the virtual organization’s minimal administration costs (8%).